A chaperone-dependent GSK3β transitional intermediate mediates activation-loop autophosphorylation

被引:229
作者
Lochhead, Pamela A.
Kinstrie, Ross
Sibbet, Gary
Rawjee, Teeara
Morrice, Nick
Cleghon, Vaughn
机构
[1] Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland
[2] Univ Dundee, Sch Life Sci, MRC, Prot Phosphorylat Unit, Dundee DD1 5EH, Scotland
关键词
D O I
10.1016/j.molcel.2006.10.009
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Glycogen synthase kinase 3 (GSK3), a key component of the insulin and wnt signaling pathways, is unusual, as it is constitutively active and is inhibited in response to upstream signals. Kinase activity is thought to be increased by intramolecular phosphorylation of a tyrosine in the activation loop (Y216 in GSK3 beta), whose timing and mechanism is undefined. We show that GSK3 beta autophosphorylates Y216 as a chaperone-dependent transitional intermediate possessing intramolecular tyrosine kinase activity and displaying different sensitivity to small-molecule inhibitors compared to mature GSK3 beta. After autophosphorylation, mature GSK3 beta is then an intermolecular serine/threonine kinase no longer requiring a chaperone. This shows that autoactivating kinases have adopted different molecular mechanisms for autophosphorylation; and for kinases such as GSK3, inhibitors that affect only the transitional intermediate would be missed in conventional drug screens.
引用
收藏
页码:627 / 633
页数:7
相关论文
共 33 条
[21]   Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation [J].
Martinez, A ;
Castro, A ;
Dorronsoro, I ;
Alonso, M .
MEDICINAL RESEARCH REVIEWS, 2002, 22 (04) :373-384
[22]   First non-ATP competitive glycogen synthase kinase 3 β (GSK-3β) inhibitors:: Thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease [J].
Martinez, A ;
Alonso, M ;
Castro, A ;
Pérez, C ;
Moreno, FJ .
JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (06) :1292-1299
[23]   Pharmacological inhibitors of glycogen synthase kinase 3 [J].
Meijer, L ;
Flajolet, M ;
Greengard, P .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2004, 25 (09) :471-480
[24]   Functional studies of Shaggy/glycogen synthase kinase 3 phosphorylation sites in Drosophila melanogaster [J].
Papadopoulou, D ;
Bianchi, MW ;
Bourouis, M .
MOLECULAR AND CELLULAR BIOLOGY, 2004, 24 (11) :4909-4919
[25]   IDENTIFICATION OF THE REGULATORY PHOSPHORYLATION SITES IN PP42/MITOGEN-ACTIVATED PROTEIN-KINASE (MAP KINASE) [J].
PAYNE, DM ;
ROSSOMANDO, AJ ;
MARTINO, P ;
ERICKSON, AK ;
HER, JH ;
SHABANOWITZ, J ;
HUNT, DF ;
WEBER, MJ ;
STURGILL, TW .
EMBO JOURNAL, 1991, 10 (04) :885-892
[26]   Hsp90 and Cdc37 - a chaperone cancer conspiracy [J].
Pearl, LH .
CURRENT OPINION IN GENETICS & DEVELOPMENT, 2005, 15 (01) :55-61
[27]   Targeting of the protein chaperone, HSP90, by the transformation suppressing agent, radicicol [J].
Sharma, SV ;
Agatsuma, T ;
Nakano, H .
ONCOGENE, 1998, 16 (20) :2639-2645
[28]   Structure of GSK3β reveals a primed phosphorylation mechanism [J].
ter Haar, E ;
Coll, JT ;
Austen, DA ;
Hsiao, HM ;
Swenson, L ;
Jain, J .
NATURE STRUCTURAL BIOLOGY, 2001, 8 (07) :593-596
[29]  
WANG QM, 1994, J BIOL CHEM, V269, P14566
[30]   INHIBITION OF HEAT-SHOCK PROTEIN HSP90-PP60(V-SRC) HETEROPROTEIN COMPLEX-FORMATION BY BENZOQUINONE ANSAMYCINS - ESSENTIAL ROLE FOR STRESS PROTEINS IN ONCOGENIC TRANSFORMATION [J].
WHITESELL, L ;
MIMNAUGH, EG ;
DECOSTA, B ;
MYERS, CE ;
NECKERS, LM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (18) :8324-8328